Decreased plasma concentrations and clinical effects of alprenolol during combined treatment with pentobarbitone in hypertension.
The antihypertensive effect of alprenolol has been studied before, during and after additional pentobarbitone treatment. The combined alprenolol-pentobarbitone treatment significantly decreased alprenolol levels by 59% and 4-hydroxyalprenolol by 24%. The effect was significant after three doses and declined over 4-5 days after pentobarbitone withdrawal. The decreased alprenolol plasma levels were associated with increased pulse rate (6%), and systolic (8%) and diastolic (9%) blood pressure. The inhibition of exercise tachycardia by alprenolol was reduced by 18% at the end of pentobarbitone treatment compared to initial monotherapy with alprenolol. The interaction is probably clinically important in those patients with hypertension and angina pectoris that are treated with barbiturates and alprenolol.
D000328:Adult; D000526:Alprenolol / Q000031:analogs & derivatives / Q000097:blood / Q000627:therapeutic use*; D001794:Blood Pressure; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D010424:Pentobarbital / Q000627:therapeutic use*; D011674:Pulse
C048019:4-hydroxyalprenolol; D000526:Alprenolol; D010424:Pentobarbital